Navigation Links
Vyvanse Capsules CII administration through 2 routes demonstrated similar pharmacokinetic profile
Date:10/22/2009

xia (four of 18 subjects). Adverse events were more common after intranasal administration, reported by 38.9 percent of participants (seven of 18), compared with 27.8 percent of participants (five of 18) after oral administration.

Vyvanse, which was introduced in the United States in July 2007 for the treatment of ADHD in children aged 6 to 12 years and approved in April 2008 to treat ADHD in adults, is currently available in six dosage strengths of 20 mg, 30 mg, 40 mg, 50 mg, 60 mg, and 70 mg.


'/>"/>

Contact: Matthew Cabrey, Shire
484-595-8248
Porter Novelli
Source:Eurekalert

0

GOOD

Page: 1 2 3

Related medicine news :

1. VYVANSE CII provided significant efficacy at 14 hours in adults with ADHD
2. GlaxoSmithKline and Shire Enter Agreement to Co-Promote Vyvanse(R) (lisdexamfetamine dimesylate) CII for Adult Attention Deficit Hyperactivity Disorder
3. VYVANSE provided behavior, inattention and math test score improvements in children with ADHD
4. Phase III pivotal results presented of VYVANSE to treat ADHD in adults
5. FDA approves VYVANSE, first and only once-daily prodrug stimulant to treat ADHD in adults
6. FDA approves additional dosage strengths of Vyvanse
7. Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track
8. VYVANSE trial in adult ADHD demonstrated significant efficacy within 1 week of daily treatment
9. Breckenridge Pharmaceutical Enters Agreement with Orit Laboratories (West Caldwell, NJ) to Market Ergocalciferol (Vitamin D) Capsules
10. Solvay Pharmaceuticals, Inc. Announces Commercial Availability of CREON(R) (Pancrelipase) Delayed-Release Capsules
11. Patients Suffering from Diabetes Now Have the Option to Suffer No More with Diabetic Free All Natural Medical Herbal Extracts Capsules
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:$232 Billion Personalized Medicine Market to Grow 11 Percent Annually, says PricewaterhouseCoopers 2$232 Billion Personalized Medicine Market to Grow 11 Percent Annually, says PricewaterhouseCoopers 3$232 Billion Personalized Medicine Market to Grow 11 Percent Annually, says PricewaterhouseCoopers 4$232 Billion Personalized Medicine Market to Grow 11 Percent Annually, says PricewaterhouseCoopers 5$232 Billion Personalized Medicine Market to Grow 11 Percent Annually, says PricewaterhouseCoopers 6Roche Diagnostics Opens State-of-the-Art Training Center in California 2ChemoCentryx Reports Additional New Data from the PROTECT-1 Study Demonstrating Traficet-EN's Effectiveness in Maintaining Remission in Patients with Crohn's Disease 2ChemoCentryx Reports Additional New Data from the PROTECT-1 Study Demonstrating Traficet-EN's Effectiveness in Maintaining Remission in Patients with Crohn's Disease 3ChemoCentryx Reports Additional New Data from the PROTECT-1 Study Demonstrating Traficet-EN's Effectiveness in Maintaining Remission in Patients with Crohn's Disease 4ChemoCentryx Reports Additional New Data from the PROTECT-1 Study Demonstrating Traficet-EN's Effectiveness in Maintaining Remission in Patients with Crohn's Disease 5ChemoCentryx Reports Additional New Data from the PROTECT-1 Study Demonstrating Traficet-EN's Effectiveness in Maintaining Remission in Patients with Crohn's Disease 6ChemoCentryx Reports Additional New Data from the PROTECT-1 Study Demonstrating Traficet-EN's Effectiveness in Maintaining Remission in Patients with Crohn's Disease 7Motorcyclist Lives On Rides On Through Organ Donation 53587 1Motorcyclist Lives On Rides On Through Organ Donation 53587 2Motorcyclist Lives On Rides On Through Organ Donation 53587 3Motorcyclist Lives On Rides On Through Organ Donation 53587 4Motorcyclist Lives On Rides On Through Organ Donation 53587 5Revised 3A Sinovac Provides Update on Clinical Trial for H1N1 Vaccine Trials 13339 1Revised 3A Sinovac Provides Update on Clinical Trial for H1N1 Vaccine Trials 13339 2Revised 3A Sinovac Provides Update on Clinical Trial for H1N1 Vaccine Trials 13339 3The World of HD Video Conferencing is Now at VideoCentric One stop Comparisons of Tandberg Polycom Lifesize Sony Emblaze VCON and Aethra 53580 1The World of HD Video Conferencing is Now at VideoCentric One stop Comparisons of Tandberg Polycom Lifesize Sony Emblaze VCON and Aethra 53580 2The World of HD Video Conferencing is Now at VideoCentric One stop Comparisons of Tandberg Polycom Lifesize Sony Emblaze VCON and Aethra 53580 3The World of HD Video Conferencing is Now at VideoCentric One stop Comparisons of Tandberg Polycom Lifesize Sony Emblaze VCON and Aethra 53580 4